Moreover, it could be hypothesized that CD38 expression levels are predictive for response to daratumumab in prostate cancer patients, as previously reported in refractory multiple myeloma [97] (Figure 1 and Table 1). This evidence concerns the gene CD38 and prostate carcinoma.